GHK-Cu is a copper-binding tripeptide — glycyl-L-histidyl-L-lysine complexed with a copper(II) ion — first identified in the 1970s as a factor present in human plasma that declines with age.^[1] It has been the subject of a long biochemistry literature, a substantial cosmetic-ingredient literature, and a smaller literature exploring injectable or systemic applications. This article summarizes what has actually been examined in each of those settings, keeping them separate because they are different literatures with different evidence bases.

The biochemistry

The GHK tripeptide binds copper with high affinity, and the copper-tripeptide complex has been studied for effects on collagen synthesis, glycosaminoglycan production, and gene expression in cultured cells. In vitro work has reported modulation of a wide range of genes, including some involved in the extracellular matrix, wound healing, and antioxidant pathways.^[1] The biochemistry is real and reasonably well characterized; the question, as always, is how much of it translates to any specific human use case.

The cosmetic-ingredient literature

GHK-Cu appears as an active ingredient in a range of topical cosmetic formulations, particularly in the anti-aging and post-procedure skincare categories. There is an in vitro and small-scale clinical literature examining topical formulations for effects on measures of skin appearance and structure.^[2] Cosmetic ingredients are regulated as cosmetics, not as drugs, which means the evidentiary standard applied to cosmetic marketing claims is different — often lower and less transparent — than the standard applied to drug claims.

A reader who encounters GHK-Cu in the topical cosmetic context should keep the framework in mind: cosmetic evidence is its own conversation, with its own limitations. It does not transfer, straightforwardly, to conclusions about injectable use.

Injectable and systemic use

The literature on injected or systemically administered GHK-Cu in humans is substantially smaller than the topical literature and considerably smaller than the in vitro literature. The reasons are practical — injectable products require sterility, endotoxin control, and pharmacokinetic characterization that topical formulations do not — and evidentiary: the studies that would establish safety and efficacy for systemic use in a defined population have not, for the most part, been conducted.

GHK-Cu sold in the research-peptide market is generally supplied as a lyophilized powder intended to be reconstituted. That form factor mirrors the injectable use case even when the labeling asserts otherwise, and the same CoA questions apply — identity by mass spectrometry, potency by HPLC, sterility, endotoxin — with the added consideration that a copper-peptide complex has its own analytical characterization requirements beyond those of a pure peptide.

Copper as a variable

The 'Cu' in GHK-Cu is not a nominal designation. Copper is a biologically active metal with its own homeostatic controls; systemic administration of copper-containing compounds is not a neutral pharmacological intervention. The relationship between the peptide-bound copper in a GHK-Cu formulation and the total copper burden delivered by a given dose is a legitimate analytical and safety question, and it is one that a serious injectable-drug development program would characterize explicitly.

Regulatory posture

GHK-Cu is not an FDA-approved drug for any indication. Topical formulations enter the cosmetic regulatory framework; injectable formulations sold as research chemicals sit outside the drug supply chain, with the same 'research use only' framing and the same limitations of that framing described elsewhere on this site. Anti-doping status is category-dependent and worth checking against current WADA lists for anyone competing under a sport-governance body.

Reading the file

GHK-Cu is a compound with a genuinely interesting biochemistry, a substantial cosmetic literature, and a much smaller systemic-use literature. Marketing that treats the three as a single evidence base — using cosmetic-context findings to support injectable-context claims, or in vitro gene-expression results to support systemic outcome claims — is running well ahead of the primary literature. Reading each context on its own terms is the more accurate frame.